Point-of-care C Reactive Protein for the Diagnosis of Lower Respiratory Tract Infection in NHS Primary Care: a Qualitative Study of Barriers and Facilitators to Adoption
Overview
Affiliations
Objectives: Point-of-care (POC) C reactive protein (CRP) is incorporated in National Institute of Health and Care Excellence (NICE) guidelines for the diagnosis of pneumonia, reduces antibiotic prescribing and is cost effective.
Aim: To determine the barriers and facilitators to adoption of POC CRP testing in National Health Service (NHS) primary care for the diagnosis of lower respiratory tract infection.
Design: The study followed a qualitative methodology based on grounded theory. The study was undertaken in 2 stages. Stage 1 consisted of semistructured interviews with 8 clinicians from Europe and the UK who use the test in routine practice, and focused on their subjective experience in the challenges of implementing POC CRP testing. Stage 2 was a multidisciplinary-facilitated workshop with NHS stakeholders to discuss barriers to adoption, impact of adoption and potential adoption scenarios. Emergent theme analysis was undertaken.
Participants: Participants included general practitioners (including those with commissioning experience), biochemists, pharmacists, clinical laboratory scientists and industry representatives from the UK and abroad.
Results: Barriers to the implementation of POC CRP exist, but successful adoption has been demonstrated abroad. Analysis highlighted 7 themes: reimbursement and incentivisation, quality control and training, laboratory services, practitioner attitudes and experiences, effects on clinic flow and workload, use in pharmacy and gaps in evidence.
Conclusions: Successful adoption models from the UK and abroad demonstrate a distinctive pattern and involve collaboration with central laboratory services. Incorporating antimicrobial stewardship into quality improvement frameworks may incentivise adoption. Further research is needed to develop scaling-up strategies to address the resourcing, clinical governance and economic impact of widespread NHS implementation.
Vogler S, Steigenberger C, Windisch F Health Policy Open. 2024; 7:100129.
PMID: 39430908 PMC: 11488418. DOI: 10.1016/j.hpopen.2024.100129.
Hoste M, Borek A, Santillo M, Roberts N, Tonkin-Crine S, Anthierens S J Antimicrob Chemother. 2024; 80(1):29-46.
PMID: 39378128 PMC: 11695907. DOI: 10.1093/jac/dkae349.
[Audit of Antibiotic Dispensing in Community Pharmacy (Happy Patient Project)].
Plaza Zamora F, Mendoza Barbero A, Molinero A, Sanchez Marcos N, Lambert M, Taxis K Farm Comunitarios. 2024; 15(4):26-36.
PMID: 39156980 PMC: 11326684. DOI: 10.33620/FC.2173-9218.(2023).28.
Ayorinde A, Ghosh I, Shaikh J, Adetunji V, Brown A, Jordan M Front Public Health. 2024; 12:1359790.
PMID: 38841670 PMC: 11150712. DOI: 10.3389/fpubh.2024.1359790.
Wilcox C, Odeh N, Clark T, Muller I, Becque T, Todd A J Antimicrob Chemother. 2024; 79(6):1441-1449.
PMID: 38708643 PMC: 11144485. DOI: 10.1093/jac/dkae127.